reports
Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing R...
Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) AUSTIN, TX and DURHAM, NC, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today announced that it has granted inducement equity awards on December 10, 2025 (the “Grant Date”) to a newly-hired non-executive officer. The inducement ...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Dec. 12, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 3,600 shares of its common stock to three newly-hired employees, with a grant date of December 9, 2025 (the "Grant Date"). The restricted stock units were granted pu...
Stitch Fix Inc: 1 director
A director at Stitch Fix Inc sold 303,450 shares at 5.188USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
Consumer Portfolio Services Inc: 1 director
A director at Consumer Portfolio Services Inc sold 100,000 shares at 8.690USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...
- Jonathan Moreland
STAA STAAR SURGICAL CO.
MYE MYERS INDUSTRIES INC.
KVHI KVH INDUSTRIES INC.
GOGO GOGO INC.
GLP GLOBAL PARTNERS LP
FAST FASTENAL COMPANY
CPSI COMPUTER PROGRAMS & SYSTEMS INC.
CNS COHEN & STEERS INC.
GAM GENERAL AMERICAN INVESTORS CO. INC.
MSM MSC INDUSTRIAL DIRECT CO. INC. CLASS A
AP AMPCO-PITTSBURGH
KYN KAYNE ANDERSON MLP INVESTMENT CO.
ICHR ICHOR HOLDINGS LTD.
CELH CELSIUS HOLDINGS INC.
SONO SONOS
AEYE AUDIOEYE INC
AVTR AVANTOR
TELA INC.
UTZ TELA BIO
ACVA UTZ BRANDS INC (A)
NEXT ACV AUCTIONS INC.
EVLV NEXT CAPITAL
BHVN EVOLV TECHNOLOGIES HLDGS INC
VANI BIOHAVEN LTD
WEST VIVANI MEDICAL INC
SMRT WESTROCK COFFEE COMPANY LLC
GTE SMARTRENT INC
ET GRAN TIERRA ENERGY INC.
MNR ENERGY TRANSFER LP
CRVO MACH NATURAL RESOURCES LP
NCDL CERVOMED INC
SPRU NUVEEN CHURCHILL DIRECT LENDING CORP
MXF SPRUCE POWER HOLDING CORP
GF THE MEXICO FUND
HYMC INC.
BATRK THE NEW GERMANY FUND
GMRE INC.
ANNX HYCROFT MINING HOLDING CORPORATION
LIBERTY MEDIA CORP
GLOBAL MEDICAL REIT INC.
ANNEXIN PHARMACEUTICALS AB (PUBL)
Shattuck Labs to Participate in Upcoming December Investor Conferences
Shattuck Labs to Participate in Upcoming December Investor Conferences AUSTIN, TX and DURHAM, NC, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today announced that Company management will participate in multiple investor conferences in December 2025. Conference Details Conference: Piper Sandler 37th Annual Heal...
TELA Bio to Participate in the Piper Sandler 37th Annual Healthcare Co...
TELA Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference MALVERN, Pa., Nov. 19, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in Piper Sandler’s 37th Annual Healthcare Conference. TELA’s management is scheduled to present at Piper Sandler’s 37th Annual Healthcare Conference at 2:30 pm ET on December 3rd, 2025. Interested parties can access the live and archived webcast at . About TELA Bio, In...
- Jonathan Moreland
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
KVHI KVH INDUSTRIES INC.
GLP GLOBAL PARTNERS LP
FOXF FOX FACTORY HOLDING CORP.
FLDM FLUIDIGM
ALG ALAMO GROUP INC.
GAM GENERAL AMERICAN INVESTORS CO. INC.
MSM MSC INDUSTRIAL DIRECT CO. INC. CLASS A
TREX TREX COMPANY INC.
ICHR ICHOR HOLDINGS LTD.
CELH CELSIUS HOLDINGS INC.
HFFG HF FOODS GROUP INC
AVTR AVANTOR
PGNY INC.
TELA PROGYNY
SMCI TELA BIO
MRVI SUPER MICRO COMPUTER
BLND INC.
BHVN MARAVAI LIFESCIENCES HOLDINGS
DRCT ETRACS DJ-UBS COMMODITY INDEX 2-4-6 BLEND
VANI BIOHAVEN LTD
GTE DIRECT DIGITAL HLDGS INC
GT VIVANI MEDICAL INC
CRVO GRAN TIERRA ENERGY INC.
NCDL GOODYEAR TIRE & RUBBER CO.
NEXT CERVOMED INC
CATX NUVEEN CHURCHILL DIRECT LENDING CORP
RMI NEXTSOURCE MATERIALS INC.
BATRK PERSPECTIVE THERAPEUTICS
GMRE INC.
RIVERNORTH OPPOR MUN INC FD INC
LIBERTY MEDIA CORP
GLOBAL MEDICAL REIT INC.
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of (i) restricted stock units covering 30,200 shares of its common stock to seventeen newly-hired employees and (ii) an option to purchase 25,000 shares of its common stock to one employee, with a gra...
- Wedbush Research
WDC WESTERN DIGITAL CORPORATION
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
FATE FATE THERAPEUTICS INC
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
AXTI AXT INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
PTGX PROTAGONIST THERAPEUTICS
ANAB ANAPTYSBIO INC.
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
ACET INC.
STTK ADICET BIO INC
TVTX SHATTUCK LABS
VRDN TRAVERE THERAPEUTICS INC
SANA VIRIDIAN THERAPEUTICS INC
PHVS SANA BIOTECHNOLOGY
DAWN PHARVARIS NV
STX DAY ONE BIOPHARMACEUTICALS INC
GFS SEAGATE TECHNOLOGY HLDGS PLC
EWTX GLOBALFOUNDRIES INC
NUVL EDGEWISE THERAPEUTICS INC
ARTV NUVALENT INC
SYRE ARTIVA BIOTHERAPEUTICS INC
RNAC SPYRE THERAPEUTICS INC.
CARTESIAN THERAPEUTICS INC
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Martin Fan
- Ritika Das
- Robert Driscoll
- Yun Zhong
TELA Bio Announces Pricing of $13.0 Million Underwritten Registered Di...
TELA Bio Announces Pricing of $13.0 Million Underwritten Registered Direct Offering of Common Stock and Pre-Funded Warrants MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the pricing of an underwritten registered direct offering of 4,189,000 shares of its common stock at a price of $1.11 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase 7,523,000 shares of common stock at an offering p...
TELA Bio Reports Third Quarter 2025 Financial Results and Refinancing ...
TELA Bio Reports Third Quarter 2025 Financial Results and Refinancing and Upsizing of Credit Facility MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights Revenue of $20.7 million, a 9% increase from the third quarter of 2024Revised full year 2025 revenue guidance of at least 16% growth over full year 2024 Recent Strategic Highli...
CPS Announces Third Quarter 2025 Earnings
CPS Announces Third Quarter 2025 Earnings Revenues of $108.4 million compared to $100.6 million in the prior year periodPretax income of $7.0 million compared to $6.9 million in the prior year periodNew contract purchases of $391.1 million in the quarter LAS VEGAS, NV, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) today announced earnings of $4.9 million, or $0.20 per diluted share, for its third quarter ended September 30, 2025. This represents an increase compared to net income of $4.8 million, or $0.20 per diluted share, in...
CPS to Host Conference Call on Third Quarter 2025 Earnings
CPS to Host Conference Call on Third Quarter 2025 Earnings LAS VEGAS, Nevada, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) today announced that it will hold a conference call on Tuesday, November 11, 2025 at 1:00 p.m. ET to discuss its third quarter 2025 operating results. Those wishing to participate can pre-register for the conference call at the following link . Registered participants will receive an email containing conference call details for dial-in options. To avoid delays, we encourage participants to dial into the c...
- Wedbush Research
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
TSLA TESLA INC
TRIP TRIPADVISOR INC.
EXPE EXPEDIA GROUP INC.
CTMX CYTOMX THERAPEUTICS INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
NFLX NETFLIX INC.
INOD INNODATA
PTGX PROTAGONIST THERAPEUTICS
NTLA INTELLIA THERAPEUTICS INC.
ANAB ANAPTYSBIO INC.
ROKU ROKU INC. CLASS A
RCKT ROCKET PHARMACEUTICALS
BKNG BOOKING HOLDINGS INC.
DNLI DENALI THERAPEUTICS INC
HEAR TURTLE BEACH CORP.
STRO SUTRO BIOPHARMA
STTK SHATTUCK LABS
ABNB AIRBNB INC. CLASS A
IMNM IMMUNOME
SANA SANA BIOTECHNOLOGY
PLTK PLAYTIKA HOLDING
TTD THE TRADE DESK
GLUE INC.
ATXS MONTE ROSA THERAPEUTICS INC
JANX ASTRIA THERAPEUTICS INC
YOU JANUX THERAPEUTICS INC
SOUN CLEAR SECURE INC
EWTX SOUNDHOUND AI INC
SYRE EDGEWISE THERAPEUTICS INC
NATL SPYRE THERAPEUTICS INC.
OS NCR ATLEOS CORPORATION
MAZE ONESTREAM INC
CBIO MAZE THERAPEUTICS INC
SNDK CRESCENT BIOPHARMA INC.
SANDISK CORP
- David Nierengarten
- Dennis Pak
- Martin Fan
Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent ...
Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights –First participants dosed in Phase 1 clinical trial of SL-325 in healthy volunteers – – Closed a private placement of up to $103 million in August 2025 to support advancement of SL-325 – – Appointments of Dan Baker, M.D., and Mona Ashiya, Ph.D. to the Board of Directors – AUSTIN, TX and DURHAM, NC, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (...
TELA Bio to Announce Third Quarter 2025 Financial Results
TELA Bio to Announce Third Quarter 2025 Financial Results MALVERN, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report third quarter 2025 financial results on Thursday, November 13, 2025. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Third Quarter Earnings Conference Call and Webcast DetailsInve...
TELA Bio Appoints William Plovanic to Board of Directors
TELA Bio Appoints William Plovanic to Board of Directors MALVERN, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- MALVERN, Pa., November 3, 2025 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA Bio”) (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of William (“Bill”) Plovanic, CFA, to its Board of Directors. Mr. Plovanic brings a distinctive combination of capital markets expertise and operational leadership in medical technology. He currently serves as Managing Director, Healthcare Equity ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.